Retinalamin in retinal dystrophy: a 46-patient long-term comparison
Observational study · 2015
- What was studied
- 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
- Main finding
- Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.
Visual acuity improved after the first course · 18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1.
Reported findings and study design
Retinalamin 5 mg by parabulbar injection daily for 10 days (50 mg per course), repeated one to two times per year. The paper compares 20 people with 5–7 years of courses, 11 with 23–25 years of courses and 15 given conventional medications.
Population or model 46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity improved after the first course | 18/31 (58.1%) with Retinalamin and 4/15 (26.7%) with conventional medications, calculated from the visual acuity categories in Table 1. | |
| Retinal pigmentary degeneration at long-term follow-up | After 23–25 years of Retinalamin, 5/9 had residual vision (0.02–0.04), 1/9 had object vision (0.1 or higher) and 3/9 had complete blindness. All 11 conventional-care patients in this diagnostic subgroup had complete blindness. | |
| Pigmentary degeneration after shorter exposure | Of 15 who received Retinalamin for the first 5–7 years, 5 retained residual vision and 10 had complete blindness at long-term assessment. |
The long-term comparison is observational. Duration groups reflect access to repeated courses, with potential differences in baseline severity and retention.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Treatment groups were defined by access to repeated courses. Selection, baseline differences and retention can influence the long-term comparison.
- The paper reports patients and eyes separately. The reported outcomes do not establish a separate independent effect for each eye.
- This study examines pigmentary degeneration and retinal abiotrophy, distinct diagnoses from the early macular degeneration dissertation.
Source details
Original journal report
Original bilingual full article, methods and Tables 1 and 4.
Sources checked
Citation
M. I. Razumovskiy, K. M. Pavlyuchenko, A. M. Razumovskaya. Retinalamin in retinal dystrophy: a 46-patient long-term comparison Ophthalmology in Russia. 2015;12(2):43–47. The DOI string carries a different page range.
Study source ↗ · DOI 10.18008/1816-5095-2015-2-41-45 · Bibliography entry · Link to this summary